Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903434 · ClinicalTrials.gov registry record · Phase 1
A Study of Evacetrapib (LY2484595) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01903434 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 60 participants.
The verdict
NCT01903434, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to measure and compare the amounts of the study drug evacetrapib found in the blood after taking two different formulations. The study has 3 periods. Participants will take each formulation by mouth at least once. A minimum of 14 days will pass between study drug doses. The safety and tolerability of the study drug will also be examined. Information about any side effects that may occur will also be collected. This study will last approximately 6 weeks.
Interventions
- DRUG Evacetrapib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01903434
The ClinicalTrials.gov registry entry for NCT01903434 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Evacetrapib is the first listed.
NCT01903434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01903434 about?
NCT01903434 is a clinical study titled "A Study of Evacetrapib (LY2484595) in Healthy Participants". The purpose of this study is to measure and compare the amounts of the study drug evacetrapib found in the blood after taking two different formulations. The study has 3 periods. Participants will take each formulation by mouth at least once. A minimum of 14 days will pass between study drug doses. ...
What is the current status of trial NCT01903434?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2013-07. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01903434?
The interventions under investigation include: Evacetrapib (DRUG).
Who is sponsoring clinical trial NCT01903434?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.